You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Jonathan Whitfield1, Laura Soucek2,3,4,5
1Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. jwhitfield@vhio.net.
MYC, a key regulator of cell growth, becomes oncogenic in cancer. New research highlights MYC inhibition as a promising cancer therapy, offering novel methods to study this complex protein.
Area of Science:
Background:
Discussion:
Key Insights:
Outlook: